Overview

A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
University Hospital, Bordeaux
Treatments:
Lapatinib